Werewolf Therapeutics (HOWL) Non Operating Income (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Non Operating Income of -$3.5 million for Q2 2026, down 692.73% year-over-year from $588466.3 in Q2 2025, and down 1236.4% on a QoQ basis from -$261000.0 in Q1 2026.
Werewolf Therapeutics (HOWL) Non Operating Income (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Non Operating Income for 7 years, with the latest figure at -$3.5 million in Q2 2026.
- Non Operating Income for Q2 2026 came in at -$3.5 million, down 692.73% year-over-year; the trailing twelve-month figure through Jun 2026 was -$3.4 million (down 2314.39% YoY), and the FY2025 annual result was -$145000.0, down 104.71% from the prior year.
- Non Operating Income eased to -$3.5 million in Q2 2026, from -$261000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.7 million in Q2 2024 and troughed at -$3.5 million in Q2 2026.
- A 5-year average of $253666.7 and a median of $414500.0 in 2022 frame the typical range for Non Operating Income.
- The widest annual swing landed in 2022, when Non Operating Income surged 8226.67%; it then sank 692.73% in 2026.
- A 5-year view of Non Operating Income shows it stood at $1.2 million in 2022, then decreased by 23.22% to $959000.0 in 2023, then tumbled by 105.42% to -$52000.0 in 2024, then soared by 2094.23% to $1.0 million in 2025, then slumped by 436.35% to -$3.5 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were -$3.5 million in Q2 2026, -$261000.0 in Q1 2026, and $1.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | -3.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.49 Mn |
| Mar 31, 2026 | -261,000.00 |
| Dec 31, 2025 | 1.04 Mn |
| Sep 30, 2025 | -644,000.00 |
| Jun 30, 2025 | -440,000.00 |
| Mar 31, 2025 | -98,000.00 |
| Dec 31, 2024 | -52,000.00 |
| Sep 30, 2024 | 451,000.00 |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 969,000.00 |
| Dec 31, 2023 | 959,000.00 |
| Sep 30, 2023 | 966,000.00 |
| Jun 30, 2023 | 969,000.00 |
| Mar 31, 2023 | 241,000.00 |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 596,000.00 |
| Jun 30, 2022 | 378,000.00 |
| Mar 31, 2022 | 23,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Sep 30, 2021 | 37,000.00 |